Live
- BRS MLA Patnam Narender Reddy Gets Relief from High Court
- Shafali Verma Dropped as India Names 16-Member Squad for December ODIs Against Australia
- Leaked! iPhone 17 Battery, Camera, Chipset, Design and Display Upgrades
- Kerala mulls increasing retirement age of govt employees to 57
- Credit, deposit growth now in line with each other in India: Report
- Very 'productive' meeting with PM Modi, says British PM Starmer
- Actor Satyadev in Bengaluru to promote Zebra movie
- Vijaya Chaitanya Palanki Leads the Development of Advanced Data Analytics Algorithms for Upsell Scoring, Churn Prediction, and Promotion Management
- Wanaparthy collector says Prajapalana Vijayotsava kaka yatra from 19 Nov to 7 Dec
- Hamas says security operation kills 20 aid truck looters
Aurobindo Pharma, Covaxx To Develop Covid-19 Vaccine For India, UNICEF
Covid-19 vaccine
Aurobindo Pharma and US-based Covaxx have entered into a license agreement to develop, commercialise and manufacture a vaccine to fight Covid-19 for India and the United Nations Children's Fund (UNICEF) agency.
Hyderabad (Telangana): Aurobindo Pharma and US-based Covaxx have entered into a license agreement to develop, commercialise and manufacture a vaccine to fight Covid-19 for India and the United Nations Children's Fund (UNICEF) agency.
Covaxx is currently conducting a phase one clinical trial for the vaccine candidate UB-61.
"We are proud to partner with Covaxx in developing the first-ever synthetic peptide-based vaccine to combat the Covid-19 pandemic," said N Govindarajan, Managing Director of Aurobindo Pharma.
"This vaccine has immense potential in eliminating shedding and hence containing the spread of pandemic," he said in a statement on Thursday.
Aurobindo has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June next year.
Under the signed agreement, Aurobindo has obtained exclusive rights to develop, manufacture and sell Covaxx's UB-612 vaccine in India and to UNICEF as well as non-exclusive rights in other select emerging and developing markets.
